Concept Life Sciences’ three new robust data at the centre of the SFN annual meeting

Announcement

Concept Life Sciences, a known contract research organisation (CRO) delivering to the global pharma and Life Sciences industry, has proudly declared that it showcased three new research posters at the 2025 Neuroscience in San Diego, California, during the annual meeting of the Society for Neuroscience (SFN), held from 15-19 November. The studies elaborated the company’s enlarged expertise in neurodegeneration, translational cell models and neuroinflammation that improves the predictability timeline of early drug discovery.  

Three studies with the poster definition

The three posters highlight how Concept Life Sciences implements suitable ex vivo and in vitro systems to model critical mechanisms, underscoring neuroinflammatory and neurodegenerative diseases.

The first study shows the development of a drug screening cascade to address selective NLRP3 inhibitors and novel potent inhibitors. This study develops a qualified, multi-level phenotypic screening cascade for exploring the future NLRP3 inflammasome inhibitors. By embedding human THP-1 cells, human iPSC-derived microglia, organotypic brain slices and primary human macrophages, the workflow serves the best of the unified functional and mechanistic readouts to improve translatability. This will lead to precise clearance in the early drug discovery.

The second study on the poster is regarding ‘In-Vitro Models of OPC Maturation and Myelination for Drug Discovery’. This study presents those in vitro assays that allow comprehensive differentiation, myelin formation and quantification of oligodendrocyte precursor cell (OPC) proliferation. By merging 3D Imaging and High-Content with metabolite quantification and gene expression analysis, the company established reproducible assays.

These assays usually secure the functional hallmarks and molecular mechanisms of OPC myelination and maturation. These models offer a translational platform to examine the compounds that might improve remyelination in disorders like ischemic stroke, Alzheimer’s disease and various sclerosis.

The third study describes elevating iPSC-derived astrocytes to leverage the discovery of novel drugs focusing on neuroinflammation. The Concept Life Sciences qualified human iPSC-derived astrocytes as a robust, reproducible model of reactive neurotoxic astrocytes. This develops a valuable assay for examining the compounds that operate the neuroinflammatory pathways.

The Neuroscience Associate Director at Concept Life Sciences, Dr Elise Malavasi, said, “Our hard work presented at 2025 Neuroscience, spotlighted how our unified biology platforms allow a valuable understanding of neurodegenerative and neuroinflammatory mechanisms. By amalgamating the primary cell-based assays, 3D models and advanced human cell systems, we offer the best translational tools to our partners that will leverage the progress and de-risk discovery towards clinical impact.”